• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Steven M. Grauer, Virginia L. Pulito, +15 authors Nicholas J Brandon
  • Chemistry, Medicine
  • The Journal of pharmacology and experimental…
  • 1 November 2009
  • Following several recent reports that suggest that dual cAMP and cGMP phosphodiesterase 10A (PDE10A) inhibitors may present a novel mechanism to treat positive symptoms of schizophrenia, we sought toContinue Reading
  • Feng Liu, Steve Grauer, +22 authors Karen L. Marquis
  • Chemistry, Medicine
  • The Journal of pharmacology and experimental…
  • 1 December 2008
  • Positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) enhance N-methyl-d-aspartate receptor function and may represent a novel approach for the treatment ofContinue Reading
  • Renza Roncarati, Carla Scali, +12 authors Georg C. Terstappen
  • Chemistry, Medicine
  • The Journal of pharmacology and experimental…
  • 1 May 2009
  • The alpha7 nicotinic acetylcholine receptor (nAChR) is a promising target for treatment of cognitive dysfunction associated with Alzheimer's disease and schizophrenia. Here, we report theContinue Reading
  • Michele P. Kelly, Sheree F. Logue, +18 authors Nicholas J Brandon
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences…
  • 4 May 2010
  • Phosphodiesterase 11A (PDE11A) is the most recently identified family of phosphodiesterases (PDEs), the only known enzymes to break down cyclic nucleotides. The tissue expression profile of this dualContinue Reading
  • Karen L. Marquis, Thomas A. Comery, +11 authors John Dunlop
  • Psychology, Medicine
  • Psychopharmacology
  • 1 December 2011
  • Rationaleα7 nicotinic acetylcholine receptor (nAChR) agonists are proposed as candidate agents for the adjunctive treatment of cognitive deficits associated with schizophrenia. Despite the pursuit ofContinue Reading